logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
K

Keun-Wook Lee

Seoul National University Bundang Hospital
H指数:55
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer

西拉帕替尼（一种ATR激酶抑制剂）联合奥拉帕尼的安全性与有效性：在晚期实体瘤中的剂量递增研究及在晚期乳腺癌中的剂量扩展研究

British Journal of Cancer
IF6.8
2026-09-300
OAAI
Juanita S. Lopez; Seock-Ah Im; Sophie Postel-Vinay; Mario Campone; Anthony B. El-Khoueiry; Wassim Abida; Tobias Arkenau; Keun-Wook Lee; Sun Young Rha; Duncan I. Jodrell; Rebecca Roylance; Itziar Irurzun-Arana; Gemma N. Jones; Natalia Lukashchuk; Christine Stephens; Conor Norris; Arsène-Bienvenu Loembé; Emma Dean; Matthew G. Krebs
Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial

Evorpacept联合曲妥珠单抗、雷莫昔单抗和紫杉醇治疗HER2-positive胃癌: 一项随机2期试验

Nature Medicine
IF50
2026-09-240
OAAI
Kohei Shitara; Zev Wainberg; Josep Tabernero; Eric Van Cutsem; Clélia Coutzac; Christelle De La Fouchardière; Jeeyun Lee; Sun Young Rha; Yoon-Koo Kang; Philip Fanning; Alison Forgie; Cherry Mao; Daniel Brickman; Jaume Pons; Athanasios C. Tsiatis; Sophia Randolph; Keun-Wook Lee
Vactosertib plus pembrolizumab in patients with non-microsatellite instability-high metastatic colorectal or gastric cancer: a multicenter, phase Ib/IIa study

Vactosertib联合pembrolizumab治疗非微卫星不稳定性高转移性结直肠癌或胃癌患者的多中心、 Ib/IIa期研究

Nature Communications
IF15.7
2026-07-210
OA
Keun-Wook Lee; Young Suk Park; Joong Bae Ahn; Young Iee Park; Jin Won Kim; Ji-Won Kim; Yong Sang Hong; Sun Young Kim; Jeeyun Lee; Seung Tae Kim; Han Sang Kim; Minkyu Heo; Saerom Kim; Seong-Jin Kim; Tae Won Kim
Survival Rates of Patients with Gastric Cancer According to Age and Sex: A Large-Scale Study Using Data from 14,739 Patients

胃癌患者的生存率按年龄和性别划分：一项基于14,739例患者数据的大规模研究

Cancer Research and Treatment
IF3.8
2026-01-014
OAAI
Choi, Yonghoon; Kim, Nayoung; Kim, Ji Hyun; Jo, Hyeong Ho; Oh, Hyeon Jeong; Lee, Hye Seung; Jun, Yu Kyung; Yoon, Hyuk; Shin, Cheol Min; Park, Young Soo; Lee, Dong Ho; Kang, So Hyun; Park, Young Suk; Ahn, Sang-Hoon; Suh, Yun-Suhk; Park, Do Joong; Kim, Hyung Ho; Kim, Ji-Won; Kim, Jin Won; Lee, Keun-Wook; Chang, Won; Lee, Yoon Jin; Lee, Kyoung Ho; Kim, Young Hoon
Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic Hospital

在三级教学医院中针对老年癌症患者开展肿瘤-老年干预模型的可行性初步研究

Cancer Research and Treatment
IF3.8
2026-01-010
OA
Kim, Jin Won; Choi, Jung-Yeon; Park, Woochan; Kang, Minsu; Seo, Jeongmin; Jung, Eun Hee; Suh, Koung Jin; Kim, Ji-Won; Kim, Se Hyun; Kim, Yu Jung; Lee, Keun-Wook; Kim, Sang-A; Lee, Ji Yun; Lee, Jeong-Ok; Bang, Soo-Mee; Kim, Kwang-il; Kim, Jee Hyun
Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer

更正：一项多中心 Ib/II 期研究，评估度鲁木单抗和 Tremelimumab 联合多西他赛在生物标志物选择的转移性胃癌患者中的二线治疗。

British Journal of Cancer
IF6.8
2025-11-110
PRE
Keun-Wook Lee; Dae Young Zang; Hyung-Don Kim; Jin-Won Kim; Bum Jun Kim; Yoon-Koo Kang; Min-Hee Ryu; Hark Kyun Kim
Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis

替雷利珠单抗与其他程序性死亡蛋白1抑制剂在晚期胃食管癌一线治疗中的疗效和安全性比较：一项系统评价和网络Meta分析

Gastric Cancer
IF5.1
2025-10-040
PRE
Jaffer A. Ajani; Maria Alsina; Markus Moehler; Keun-Wook Lee; Wenxi Tang; Jason Steenkamp; Emily Prentiss; Kaijun Wang; Becky Hooper; Lin Zhan
Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial

头颈部鳞状细胞癌中Alpelisib对不同PIK3CA突变位点的差异性疗效：来自KCSG HN 15-16 TRIUMPH试验的分析

CANCER RESEARCH AND TREATMENT
IF3.8
2025-10-011
PRE
Kim, Kyoo Hyun; Hwang, Shinwon; Kim, Min Kyoung; Park, Keon-Uk; Yun, Tak; Lee, Keun-Wook; Kim, Joo Hang; Keam, Bhumsuk; Cho, Byoung Chul; Oh, So Yeon; Cho, Sang Hee; Kim, Sangwoo; Kim, Sung-Bae; Hong, Min Hee; Kim, Hye Ryun
Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma

早期生长反应1作为PD-L1表达和免疫逃逸的关键调节因子在结外NK/T细胞淋巴瘤中的作用

Blood Cancer Journal
IF11.6
2025-06-130
OAAI
Ji Yun Lee; Kui-Jin Kim; Woochan Park; Jeongmin Seo; Minsu Kang; Eun Hee Jung; Sang-A Kim; Koung Jin Suh; Ji-Won Kim; Se Hyun Kim; Jeong-Ok Lee; Jin Won Kim; Yu Jung Kim; Keun-Wook Lee; Jee Hyun Kim; Soo-Mee Bang; Tae Min Kim; Jin Ho Paik
Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer

转移性胃癌患者接受姑息性二线紫杉醇联合雷莫芦单抗治疗前后血浆游离DNA的配对分析

GASTRIC CANCER
IF5.1
2025-03-270
OA
Kim, Ji-Won; Kyung, Dong Soo; Ko, Won Yeong; Kim, Hwang-Phill; Hwang, Sung-Hyun; Kim, Kui-Jin; Lee, Ju Hyun; Seo, Jeongmin; Kang, Minsu; Jung, Eun Hee; Suh, Koung Jin; Kim, Se Hyun; Kim, Jin Won; Kim, Yu Jung; Kim, Jee Hyun; Lee, Keun-Wook
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的晚期胃癌: 原理305的回顾性分析

ADVANCES IN THERAPY
IF4
2025-03-010
OAAI
Moehler, Markus; Oh, Do-Youn; Kato, Ken; Arkenau, Tobias; Tabernero, Josep; Lee, Keun-Wook; Rha, Sun Young; Hirano, Hidekazu; Spigel, David; Yamaguchi, Kensei; Wyrwicz, Lucjan; Disel, Umut; Pazo-Cid, Roberto A.; Fornaro, Lorenzo; Xu, Yaling; Sheng, Tao; Yang, Silu; Kadva, Alysha; Cruz-Correa, Marcia; Xu, Rui-Hua
Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital
SCIENTIFIC REPORTS
IF3.9
2025-01-160
OAAI
Kim, Jin Won; Na, Hee Young; Lee, Sejoon; Kim, Ji-Won; Suh, Koung Jin; Kim, Se Hyun; Kim, Yu Jung; Lee, Keun-Wook; Lee, Jong Seok; Kim, Jaihwan; Hwang, Jin-Hyeok; Hwang, Kihwan; Kim, Chae-Yong; Kim, Yong Beom; Ahn, Soomin; Lee, Kyu Sang; Kim, Hyojin; Lee, Hye Seung; Park, So Yeon; Choe, Gheeyoung; Kim, Jee Hyun; Chung, Jin-Haeng
Association of TP53 Mutation Status and Sex with Clinical Outcome in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study

TP53突变状态与性别对接受免疫检查点抑制剂治疗的非小细胞肺癌患者临床结局的影响：一项回顾性队列研究

CANCER RESEARCH AND TREATMENT
IF3.8
2025-01-151
OA
Choi, Songji; Kim, Se Hyun; Lee, Sejoon; Seo, Jeongmin; Kang, Minsu; Jung, Eun Hee; Kim, Sang-A; Suh, Koung Jin; Lee, Ji Yun; Kim, Ji-Won; Kim, Jin Won; Lee, Jeong-Ok; Kim, Yu Jung; Lee, Keun-Wook; Kim, Jee Hyun; Bang, Soo-Mee; Lee, Jong Seok
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis

贝马妥珠单抗联合mFOLFOX6作为东亚FGFR2b-overexpressing局部晚期或转移性胃/胃食管交界癌患者的一线治疗: FIGHT最终分析亚组

GASTRIC CANCER
IF5.1
2024-06-112
OAAI
Kang, Yoon-Koo; Qin, Shukui; Lee, Keun-Wook; Oh, Sang Cheul; Kim, In-Ho; Kim, Jong Gwang; Li, Yong; Yan, Zhuchen; Li, Jin; Bai, Li-Yuan; Chan, Catherine; Yusuf, Akeem; Zahlten-Kuemeli, Anita; Taylor, Kate; Yamaguchi, Kensei
Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

在晚期胃癌患者中，三线免疫检查点抑制剂与基于伊立替康的化疗的真实世界结果: 韩国多中心研究 (KCSG ST22-06)

BMC CANCER
IF3.4
2024-02-232
OAAI
Lim, Sung Hee; Lee, Keun-Wook; Kim, Jae-Joon; Im, Hyeon-Su; Kim, In-Ho; Han, Hye Sook; Koo, Dong-Hoe; Cho, Jang Ho; Maeng, Chi Hoon; Lee, Min-Young; Lee, Hyo Jin; Kim, Jwa Hoon; Park, Sang Gon; Jung, Joo Young; Shin, Seong-Hoon; Kim, Ki Hyang; Kim, Hyeyeong; Oh, So Yeon; Kang, Minsu; Jung, Minkyu; Rha, Sun Young

研究方向

暂未获取到该数据
J
Jin Won Kim
H 指数:45论文数:508被引数:9,515
J
Jee Hyun Kim
H 指数:53论文数:491被引数:1.4万
J
Ji‐Won Kim
H 指数:29论文数:263被引数:3,282
Y
Yu Jung Kim
H 指数:46论文数:383被引数:8,912
S
Soo‐Mee Bang
H 指数:42论文数:480被引数:7,687
H
Hye Seung Lee
H 指数:79论文数:648被引数:2.4万
S
Se Hyun Kim
H 指数:41论文数:384被引数:7,653
J
Jong Seok Lee
H 指数:42论文数:215被引数:1.1万
D
Do‐Youn Oh
H 指数:81论文数:950被引数:4.3万
J
Jeong‐Ok Lee
H 指数:30论文数:244被引数:3,501